Medicine
Zynrelef 65.7143 mg/1.97143 mg per 2.3 mL injection
Zynrelef 65.7143 mg/1.97143 mg per 2.3 mL injection is a prescription medicine containing Bupivacaine and Meloxicam for infiltration use, marketed by Heron Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store ZYNRELEF kits at 20°C to 25°C (68°F to 77°F) with excursions permitted…
Key facts
- Active ingredient (INN)
- Bupivacaine and Meloxicam
- Brand
- Zynrelef
- Strength
- 65.7143 mg/1.97143 mg per 2.3 mL
- Dosage form
- Injection
- Route
- Infiltration
- Packs
- 1 carton of 2.3 mL
- Marketing authorisation holder
- Heron Therapeutics
- Manufacturer
- Heron Therapeutics
- Origin register
- US FDA, United States
- Storage
- Store ZYNRELEF kits at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). If ZYNRELEF vials are removed from the kit, store them at controlled room temperature. Protect from moisture and light. Protect from light during storage.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N01B Local anesthetic
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 December 2024
- Identifiers
- RxCUI 2560306, 2560308, 2560309 +5DailyMed set ID dab484a7-9353-43ba-9e74-7fab910c712bNDC 47426-503Application NDA211988
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 carton in 1 kit / 1 vial, single-dose in 1 carton / 2.3 mL in 1 vial, single-dose | 47426-503-01 | Heron Therapeutics | 1 December 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Bupivacaine and Meloxicam
Clinical summary
Bupivacaine and Meloxicam is a fixed-dose combination of an amide local anesthetic and a nonsteroidal anti-inflammatory drug indicated in adults for postsurgical analgesia for up to 72 hours after. MedsAcross supplies Bupivacaine and Meloxicam for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Bupivacaine and MeloxicamFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- ZYNRELEF prescribing information (Heron Therapeutics) · U.S. National Library of Medicine, DailyMed
Need Zynrelef 65.7143 mg/1.97143 mg per 2.3 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.